[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
霍文萍, 金洪传. 晚期胰腺癌内科治疗进展[J]. 临床荟萃, 2020, 35(8): 761-765.
|
[3]
|
郭俊超, 赵玉沛. 多药耐药基因与胰腺癌化疗[J]. 胰腺病学, 2002, 2(4): 247-249.
|
[4]
|
Von Hoff, D.D., Ervin, T., Arena, F.P., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. https://doi.org/10.1056/NEJMoa1304369
|
[5]
|
Ueno, H., Ioka, T., Ikeda, M., et al. (2013) Randomized Phase III Study of Gemcitabine plus S-1, S-1 Alone, or Gemcitabine Alone in Patients with Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. Journal of Clinical Oncology, 31, 1640-1648. https://doi.org/10.1200/JCO.2012.43.3680
|
[6]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open30 Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[7]
|
Bruchbacher, A., Lemberger, U., Hassler, M.R., et al. (2020) PD1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Current Opinion in Urology, 30, 534-541. https://doi.org/10.1097/MOU.0000000000000788
|
[8]
|
Tang, B., Chi, Z., Chen, Y., et al. (2020) Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clinical Cancer Research, 26, 4250-4259. https://doi.org/10.1158/1078-0432.CCR-19-3922
|
[9]
|
Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non- Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135.
https://doi.org/10.1056/NEJMoa1504627
|
[10]
|
Wang, F., Wei, X.L., Wang, F.H., et al. (2019) Safety, Efficacy and Tumor Mutational Burden as a Biomarker of Overall Survival Benefit in Chemo-Refractory Gastric Cancer Treated with Toripalimab, a PD-1 Antibody in Phase Ib/II Clinical Trial NCT02915432. Annals of Oncology, 30, 1479-1486. https://doi.org/10.1093/annonc/mdz197
|
[11]
|
Lv, J.W., Li, J.Y., Luo, L.N., et al. (2019) Comparative Safety and Efficacy of Anti-PD-1 Monotherapy, Chemotherapy Alone, and Their Combination Therapy in Advanced Nasopharyngeal Carcinoma: Findings from Recent Advances in Landmark Trials. Journal for ImmunoTherapy of Cancer, 7, 159. https://doi.org/10.1186/s40425-019-0636-7
|
[12]
|
Liu, J., Liu, Q., Li, Y., et al. (2020) Efficacy and Safety of Camrelizumab Combined with Apatinib in Advanced Triple-Negative Breast Cancer: An Open-Label Phase II Trial. Journal for ImmunoTherapy of Cancer, 8, e000696.
https://doi.org/10.1136/jitc-2020-000696
|
[13]
|
Ferris, R.L., Blumenschein, G., Fayette, J., et al. (2018) Nivolumab vs Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: 2-Year Long-Term Survival Update of CheckMate 141 with Analyses by Tumor PD-L1 Expression. Oral Oncology, 81, 45-51. https://doi.org/10.1016/j.oraloncology.2018.04.008
|
[14]
|
Jiang, H., Zheng, Y., Qian, J., et al. (2020) Safety and Efficacy of Sintilimab Combined with Oxaliplatin/Capecitabine as First-Line Treatment in Patients with Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in a Phase Ib Clinical Trial. BMC Cancer, 20, 760. https://doi.org/10.1186/s12885-020-07251-z
|
[15]
|
Weiss, G.J., Blaydorn, L., Beck, J., et al. (2018) Phase Ib/II Study of Gemcitabine, Nab-Paclitaxel, and Pembrolizumab in Metastatic Pancreatic Adenocarcinoma. Investigational New Drugs, 36, 96-102.
https://doi.org/10.1007/s10637-017-0525-1
|
[16]
|
Kamath, S.D., Kalyan, A., Kircher, S., et al. (2020) Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist, 25, e808-e815. https://doi.org/10.1634/theoncologist.2019-0473
|
[17]
|
Royal, R.E., Levy, C., Turner, K., et al. (2010) Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma. Journal of Immunotherapy, 33, 828-833.
https://doi.org/10.1097/CJI.0b013e3181eec14c
|
[18]
|
O’Reilly, E.M., Oh, D.Y., Dhani, N., et al. (2019) Durvalumab with or without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, 1431-1438.
https://doi.org/10.1001/jamaoncol.2019.1588
|
[19]
|
Koikawa, K., Kibe, S., Suizu, F., et al. (2021) Targeting Pin1 Renders Pancreatic Cancer Eradicable by Synergizing with Immunochemotherapy. Cell, 184, 4753-4771. https://doi.org/10.1016/j.cell.2021.07.020
|